You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for SC 560
SC 560 is a highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.009 and 6.3 μM for COX-1 and COX-2 respectively). Inhibits COX-1-derived platelet thromboxane B2, gastric PGE2 and dermal PDE2 production. Significantly reduces ovarian surface epithelial tumor growth in vivo. Orally active.
Technical Data for SC 560
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for SC 560
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for SC 560
The following data is based on the product molecular weight 352.74. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.83 mL||14.17 mL||28.35 mL|
|5 mM||0.57 mL||2.83 mL||5.67 mL|
|10 mM||0.28 mL||1.42 mL||2.83 mL|
|50 mM||0.06 mL||0.28 mL||0.57 mL|
References for SC 560
References are publications that support the biological activity of the product.
Daikoku et al (2005) Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 65 3735 PMID: 15867369
Takeuchi et al (2005) COX inhibition and NSAID-induced gastric damage - roles in various pathogenic events. Curr.Top.Med.Chem. 5 475 PMID: 15974942
Smith et al (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 95 13313 PMID: 9789085
If you know of a relevant reference for SC 560, please let us know.
View Related Products by Product Action
Keywords: SC 560, SC 560 supplier, Cyclooxygenase, COX-1, inhibitors, inhibits, Oxygenases, Oxidases, SC560, 1550, Tocris Bioscience
1 Citation for SC 560
Citations are publications that use Tocris products. Selected citations for SC 560 include:
Fritz et al (2016) Prostaglandin-dependent modulation of DArgic neurotransmission elicits inflammation-induced aversion in mice. J Clin Invest 126 695 PMID: 26690700
Do you know of a great paper that uses SC 560 from Tocris? Please let us know.
Reviews for SC 560
Average Rating: 5 (Based on 1 Review.)
Have you used SC 560?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
It is a higly lipophilic COX-1 inhibitor. It decreased tACPD-induced prostaglandin E2 in rat brain slice.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.